#Multiple Myeloma Therapeutics Market Multiple Myeloma Therapeutics Market Trends Multiple Myeloma Therapeutics Market Growth Multiple Myelom

[harshnews]

Hematologic Malignancies Market Size, Share, Trends, Growth and Competitive Analysis

"Global Hematologic Malignancies Market – Industry Trends and Forecast to 2029

Global Hematologic Malignancies Market, By Type (Leukaemia, Lymphoma, Myeloma), Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), Diagnosis (Blood Tests, Biopsy, Imaging Tests, Others), Route of Administration (Oral, Parenteral, Others), Dosage Form (Tablets, Capsules, Injections, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Access Full 350 Pages PDF Report @

**Segments**

- **Type**: The hematologic malignancies market can be segmented based on the type of malignancy, including leukemia, lymphoma, and multiple myeloma. Leukemia is a cancer of the blood cells, while lymphoma affects the lymphatic system. Multiple myeloma, on the other hand, is a cancer that forms in a type of white blood cell called a plasma cell.

- **Treatment**: Segmentation based on treatment modalities includes chemotherapy, immunotherapy, targeted therapy, stem cell transplant, and others. Chemotherapy is a common treatment for hematologic malignancies that involves the use of drugs to kill cancer cells. Immunotherapy utilizes the body's immune system to fight cancer cells, while targeted therapy focuses on specific molecules involved in cancer growth.

- **End-User**: The market can also be segmented by end-user, such as hospitals, specialty clinics, research institutes, and others. Hospitals are the primary point of care for hematologic malignancies patients, where they receive diagnosis, treatment, and follow-up care. Specialty clinics may offer specialized treatments or clinical trials for these conditions.

**Market Players**

- **Roche**: A leading player in the hematologic malignancies market, Roche offers a range of innovative therapies and diagnostic tools for leukemia, lymphoma, and multiple myeloma. The company's commitment to research and development has resulted in groundbreaking treatments that improve patient outcomes.

- **Johnson & Johnson**: With a focus on cutting-edge oncology therapies, Johnson & Johnson has made significant advancements in the treatment of hematologic malignancies. The company's portfolio includes novel drugs that target specific cancer pathways, providing new options for patients.

- **Novartis**: Known for its expertise in precision medicine, Novartis has developed several targeted therapies for hematologic malignancies. By identifying genetic mutations driving cancer growth, Novartis delivers personalized treatments that are more effective and less toxic for patients.

- **AbbVie**:AbbVie is a key player in the hematologic malignancies market, known for its strong focus on developing innovative therapies for various types of blood cancers. The company's robust pipeline includes potential treatments for leukemia, lymphoma, and multiple myeloma, leveraging cutting-edge technologies and research to address unmet medical needs in this space. AbbVie's commitment to oncology research and development has led to the introduction of novel treatment options that aim to improve patient outcomes and quality of life.

In the competitive landscape of the hematologic malignancies market, AbbVie distinguishes itself through a combination of strategic partnerships, investments in research, and a patient-centric approach to drug development. The company's collaborative efforts with academic institutions, research organizations, and other industry partners have resulted in the acceleration of novel therapeutic solutions for blood cancers. By prioritizing patient needs and engaging in meaningful dialogue with healthcare providers, AbbVie continues to shape the future of hematologic oncology with a focus on personalized medicine and targeted therapies.

AbbVie's portfolio of hematologic malignancy treatments encompasses a diverse range of modalities, including small molecule inhibitors, monoclonal antibodies, and immunotherapies. These innovative therapies target specific pathways and molecular mechanisms involved in the development and progression of blood cancers, offering new hope for patients who may not have responded to conventional treatments. By leveraging its expertise in precision medicine and biomarker-driven approaches, AbbVie continues to advance the field of hematologic oncology with a strong emphasis on tailored treatment regimens that consider individual patient characteristics and disease profiles.

In addition to its focus on drug development, AbbVie also plays a crucial role in raising awareness about hematologic malignancies and promoting early detection and diagnosis. Through educational initiatives, patient advocacy programs, and community engagement efforts, the company strives to empower patients, caregivers, and healthcare professionals with the knowledge and resources needed to effectively manage blood cancers. By fostering a culture of collaboration and knowledge-sharing, AbbVie contributes to the overall**Global Hematologic Malignancies Market Analysis**

- **Type**: The global hematologic malignancies market, segmented by type, includes leukemia, lymphoma, and multiple myeloma. With advancements in precision medicine and targeted therapies, the market is witnessing a shift towards personalized treatment regimens tailored to the specific type of malignancy, driving growth in the segment.

- **Therapy Type**: The market segmented by therapy type comprises chemotherapy, immunotherapy, and targeted therapy, among others. The rising prevalence of hematologic malignancies and the increasing adoption of novel treatment approaches are driving the demand for innovative therapies, leading to significant market growth in this segment.

- **Diagnosis**: Diagnostic modalities such as blood tests, biopsies, imaging tests, and others play a crucial role in the early detection and management of hematologic malignancies. The emphasis on early diagnosis and personalized medicine is driving the market for diagnostic tools, contributing to the overall growth of the hematologic malignancies market.

- **Route of Administration**: Different routes of administration, including oral, parenteral, and others, offer varied options for delivering hematologic malignancy treatments. The convenience and efficacy of different administration routes influence patient compliance and treatment outcomes, shaping the market dynamics in this segment.

- **Dosage Form**: The market segmented by dosage form includes tablets, capsules, injections, and others. The availability of diverse dosage forms caters to patient preferences and treatment needs, promoting adherence and enhancing the overall therapeutic outcomes in

Key points covered in the report: -

The pivotal aspect considered in the global Hematologic Malignancies Market report consists of the major competitors functioning in the global market.

The report includes profiles of companies with prominent positions in the global market.

The sales, corporate strategies and technical capabilities of key manufacturers are also mentioned in the report.

The driving factors for the growth of the global Hematologic Malignancies Market are thoroughly explained along with in-depth descriptions of the industry end users.

The report also elucidates important application segments of the global market to readers/users.

This report performs a SWOT analysis of the market. In the final section, the report recalls the sentiments and perspectives of industry-prepared and trained experts.

The experts also evaluate the export/import policies that might propel the growth of the Global Hematologic Malignancies Market.

The Global Hematologic Malignancies Market report provides valuable information for policymakers, investors, stakeholders, service providers, producers, suppliers, and organizations operating in the industry and looking to purchase this research document.

TABLE OF CONTENTS

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers and Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

Countries Studied:

North America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)

Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)

Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)

Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Browse Trending Reports:

Thermal Imaging Cameras Market Baby Food Market Thin Film Encapsulation Market Paper Coating Materials Market Protein Engineering Market Psoriasis Treatment Market Whole Exome Sequencing Market Std Diagnostics Market Medication Delivery Systems Market Lane Keep Assist System Market Liquid Synthetic Rubber Market Mainframe Market Myxoid Round Cell Liposarcoma Drug Market Hematology Analyzer Market Low Differential Pressure Sensor Market Biofuel Enzyme Market Aroma Ingredients Market Coconut Water Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"

[stevenwilliam12]

Multiple Myeloma: Advancements and Future Outlook in Treatment

Multiple Myeloma, the second most common form of blood cancer following non-Hodgkin lymphoma, is characterized by the proliferation of malignant plasma cells in the bone marrow. These abnormal cells outnumber healthy blood cells, severely compromising the body's ability to function and fight infections. Early diagnosis and appropriate treatment are critical to managing the disease. Multiple Myeloma presents in various forms, including symptomatic (active disease), asymptomatic (smoldering myeloma), solitary plasmacytoma, and rare plasma cell leukemia, each requiring tailored diagnostic and therapeutic strategies.

Rising Prevalence and Demographic Trends

The prevalence of Multiple Myeloma is rising, especially in the elderly population. The incidence rate is highest among older adults, with over half of the cases diagnosed in males. This demographic shift is influencing the Multiple Myeloma drug, with a greater focus on therapies suited to the aging population.

Current Treatment Options and Therapeutic Innovations

Historically, Multiple Myeloma treatment has centered around chemotherapy, corticosteroids, and stem cell transplantation. However, the treatment landscape has evolved with the introduction of new therapies such as Proteasome Inhibitors, Immunomodulating Agents, Histone Deacetylase (HDAC) Inhibitors, Monoclonal Antibodies, and groundbreaking CAR-T cell therapies.

Recent advancements include:

BLENREP (2020), an anti-BCMA immunoconjugate.

NINLARO (2015), the first oral proteasome inhibitor.

EMPLICITI (2015), which enhances immune response.

TECVAYLI (2022), a bispecific antibody redirecting T-cells.

DARZALEX (2015) and TALVEY (2023), targeting CD38 and refractory cases, respectively.

These therapies have extended survival rates and improved the quality of life for patients, making them dependent on continuous treatment.

Advances in Relapsed/Refractory Treatment

The treatment landscape for relapsed or refractory Multiple Myeloma is rapidly evolving, with FDA approvals of CAR-T therapies like ABECMA and CARVYKTI. Companies like Pfizer, Johnson & Johnson, and GSK are competing in this market, with their innovative therapies shaping the future of treatment. Despite challenges like the high cost of CAR-T therapies, ongoing improvements may enhance their accessibility.

Dominant Players and Market Trends

Bristol Myers Squibb (BMS) and Janssen (a subsidiary of Johnson & Johnson) dominate the Multiple Myeloma treatment market with their robust portfolios. Janssen's DARZALEX and TECVAYLI, along with BMS's CAR-T therapy ABECMA, are setting the standard in treatment innovation.

Moreover, the expiration of patents on drugs like REVLIMID has led to generic competition, but companies like BMS are focusing on new therapies such as CELMoDs (Iberdomide and Mezigdomide) to maintain their market presence.

Future Outlook

The Multiple Myeloma treatment market, valued at USD 21,300 million in 2023, is poised for significant growth through 2034. Factors such as rising incidence rates, adoption of newer treatments, and a strong pipeline of emerging therapies will drive this growth. Investment in research and development will be critical in introducing more effective treatments, particularly for a growing elderly population.

Conclusion

Multiple Myeloma treatment is undergoing a transformative period, with new therapies improving patient outcomes and expanding options for relapsed or refractory cases. As the market continues to grow, ongoing innovation and investment will be key to addressing the needs of patients and advancing treatment paradigms.

[poonamcmi]

Bortezomib Market Estimated to Witness High Growth Owing to Rising Adoption of Proteasome Inhibitors

The bortezomib market is primarily driven by high incidence and prevalence of multiple myeloma across the globe. Bortezomib, which is commonly sold under the brand name Velcade among others, is a proteasome inhibitor primarily used for the treatment of multiple myeloma and mantle cell lymphoma.

The global proteasome inhibitor drug market size is valued at approximately US$ 24.54 million in 2024 and is expected to register a CAGR of 4.7% over the forecast period of 2024-2031. The introduction of novel proteasome inhibitors and their increasing adoption in the treatment of cancer are the major factors anticipated to propel market growth. Key Takeaways

Key players operating in the bortezomib market are Hikma Pharmaceuticals, Pfizer, Meitheal Pharmaceuticals, Novartis International AG, Bristol Myers Squibb, NATCO Pharma, Teva Pharmaceuticals, Dr. Reddy's Laboratories, Gland Pharma, Shilpa Medicare, Qilu Pharmaceutical, Scion Pharmaceuticals, Farmhispania Group, Coresyn, Chem-Stone (Guangzhou), Hubei Honch Pharmaceutical, Vinkem Labs, Icrom, TAPI Teva, and Chengdu Aslee Biopharmaceuticals.

The introduction of generic versions of Bortezomib Market Demand has led to increased adoption and lowered treatment costs. Moreover, ongoing clinical trials evaluating the efficacy of bortezomib in other cancer indications are expected to expand the eligible patient pool. Technological advancements in proteasome inhibitor development focused on overcoming resistance, reducing toxicity, and novel delivery systems are further anticipated to support market growth. Market Drivers

The primary factors driving the growth of the global bortezomib market include rising prevalence of multiple myeloma globally, increasing adoption of proteasome inhibitors in treatment regimens, availability of generic versions, and ongoing clinical research evaluating the efficacy of bortezomib in other cancer indications. Additionally, improving healthcare infrastructure and expenditures in emerging economies will further support the market growth during the forecast period. Current challenges in Bortezomib Market

The Bortezomib Market Size And Trends  faces several challenges primarily due to the presence of alternative therapeutic options for treating multiple myeloma (MM). Some of the major challenges include increasing generic competition from drugs like ixazomib and daratumumab which are leading to lower sales of bortezomib drugs. Further, the patents of bortezomib drugs have expired in several regions making them available in generic forms at lower costs. This increasing availability of low-cost generics is a major challenge faced by innovator bortezomib drug companies. Additionally, the adverse side effects associated with bortezomib drugs like neuropathy and thrombocytopenia require close patient monitoring during treatment posing operational challenges. Stringent regulations for drug approval is another regulatory challenge for new market entrants. SWOT Analysis

Strength: Well-established drug with proven efficacy and safety profile in treating MM. It was the first proteasome inhibitor approved and remains a standard of care. Weakness: Patent expiry has led to availability of low-cost generics reducing sales of innovator brands. Further, it causes serious side effects like neuropathy requiring cautious use. Opportunity: Emerging economies with growing cancer burden and healthcare spending present an opportunity. Combination therapies with other anti-MM drugs can boost its use further. Threats: Increasing competition from newer oral proteasome inhibitors and monoclonal antibody based therapies poses pricing and market share threats. Stringent regulations for approval delays market entry of new players.

Geographical regions with high market concentration

In terms of value, North America accounts for the largest share of over 40% of the global bortezomib market led by the US. This is due to established healthcare infrastructure and higher adoption of innovative therapies. Europe is the second major regional market with a value share of over 30% supported by favourable reimbursement policies. The Asia Pacific region is projected to be the fastest growing market during the forecast period due to rising healthcare expenditure, growing cancer incidence and increasing demand for cancer treatments from middle-income countries like China and India. Fastest growing geographical region

The Asia Pacific region is poised to exhibit the highest growth rate during the forecast period in the global bortezomib market. This is attributed to rising disposable incomes, growing awareness about cancer treatments, expansion of healthcare facilities and increasing private sector investment in pharmaceutical research in emerging economies like China and India. Large patient pools undergoing cancer treatment in Asia present lucrative opportunities for bortezomib drug makers looking to tap high future growth potential in this region. Get More Insights On, Bortezomib Market For More Insights Discover the Report In language that Resonates with you French, German, Italian, Russian, Chinese, Korean About Author: Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

[heathcareforallworld]

Velcade Market Size, Share, Industry Trends, and Forecast 2032

Introduction

Velcade, also known by its generic name bortezomib, is a proteasome inhibitor used primarily in the treatment of multiple myeloma and mantle cell lymphoma. Since its approval, Velcade has significantly impacted the oncology market, offering a promising therapeutic option for patients with these malignancies. The global Velcade market is characterized by its dynamic nature, driven by advancements in oncology research, increasing incidence of hematologic cancers, and a growing focus on personalized medicine.

Market Size and Growth Dynamics

Velcade Market Size was estimated at 1.76 (USD Billion) in 2023. The Velcade Market Industry is expected to grow from 1.83(USD Billion) in 2024 to 2.5 (USD Billion) by 2032. The Velcade Market CAGR (growth rate) is expected to be around 4.01% during the forecast period (2024 - 2032). This growth is fueled by the rising prevalence of multiple myeloma and other related cancers, which are increasingly being diagnosed due to advances in diagnostic technologies. Furthermore, the aging population, which is more susceptible to cancer, is also contributing to the expanding market.

North America holds the largest market share, attributed to the region's advanced healthcare infrastructure, high adoption rates of new therapies, and a strong focus on research and development. Europe follows closely, driven by similar factors. However, the Asia-Pacific region is expected to witness the fastest growth during the forecast period, spurred by increasing healthcare expenditures, improving access to cancer treatments, and rising awareness about hematologic cancers.

Market Share Analysis

Velcade, originally developed by Millennium Pharmaceuticals and marketed by Takeda Oncology, has maintained a dominant position in the proteasome inhibitor segment. Its efficacy, safety profile, and first-mover advantage have contributed to its strong market share. However, with the expiration of key patents, the market has seen the entry of generic versions, which has led to increased competition and a shift in market dynamics.

The introduction of generics has made the treatment more accessible, particularly in developing regions, but it has also put pressure on the market share of branded Velcade. Despite this, the brand continues to hold a significant share due to its established presence and the trust it has garnered among healthcare professionals.

Industry Trends

Several key trends are shaping the Velcade market:

Rise of Combination Therapies: The use of Velcade in combination with other drugs, such as lenalidomide and dexamethasone, is becoming increasingly common. These combination therapies have shown improved efficacy and are becoming a standard of care in multiple myeloma treatment protocols.

Focus on Personalized Medicine: With the growing emphasis on personalized medicine, there is a trend towards tailoring treatments based on individual patient profiles, which includes genetic makeup and disease characteristics. This approach is expected to drive demand for Velcade as part of personalized treatment regimens.

Increased Research and Development: The oncology sector continues to see significant investment in research and development, leading to the discovery of new therapeutic targets and treatment options. While this fosters innovation, it also intensifies competition as new drugs enter the market.

Patent Expirations and Generic Competition: The expiration of Velcade’s patents has opened the market to generic competition, leading to reduced prices and increased accessibility. This trend is expected to continue, particularly in cost-sensitive markets.

Expanding Indications: Research is ongoing to explore the potential of Velcade in treating other cancers and conditions beyond multiple myeloma and mantle cell lymphoma. If successful, these efforts could lead to new indications, further driving market growth.

Forecast Through 2032

The Velcade Market CAGR (growth rate) is expected to be around 4.01% during the forecast period (2024 - 2032). Key drivers of this growth include the increasing global cancer burden, advancements in cancer therapy, and the expansion of healthcare infrastructure in emerging markets.

However, challenges such as the rising cost of cancer treatment, the availability of alternative therapies, and regulatory hurdles may pose risks to market expansion. Additionally, the shift towards biosimilars and generics is likely to impact the market dynamics, particularly in terms of pricing and market share distribution.

The forecast period is also expected to witness a greater emphasis on real-world evidence and outcome-based reimbursement models, which could influence the adoption of Velcade and its competitors.

Conclusion

The Velcade market is poised for significant growth in the coming years, driven by a combination of factors including rising cancer incidence, advancements in treatment protocols, and the expanding reach of healthcare services. While challenges such as generic competition and pricing pressures exist, the overall outlook remains positive, with opportunities for growth in emerging markets and through the development of new therapeutic indications. As the oncology landscape continues to evolve, Velcade is expected to remain a key player, contributing to improved outcomes for patients worldwide.

[wellnessweb]

Globalization and Market Expansion in Multiple Myeloma

The Multiple Myeloma Market size was estimated at USD 24.01 Billion In 2023 & is estimated to reach USD 59.45 Billion by 2032 and increase at a compound annual growth rate of 10.6% between 2024 and 2032.The Multiple Myeloma market is characterized by a dynamic interplay of research, treatment advancements, and patient-centric care initiatives. As one of the most prevalent hematologic cancers, it continuously draws attention from pharmaceutical innovators and healthcare providers alike. Recent years have witnessed a surge in targeted therapies, immunotherapies, and personalized medicine approaches tailored to combatting its complexities. This evolving landscape not only fosters competition among biopharmaceutical companies but also emphasizes the importance of early detection and multidisciplinary treatment strategies. With ongoing clinical trials promising novel therapeutic avenues, the Multiple Myeloma market remains poised for further breakthroughs in extending patient survival and enhancing quality of life.

The Multiple Myeloma Market  research study for the term also includes a variety of business opportunities and growth potential. A business plan detailing market risks and constraints as well as the effects of various regulatory regimes is given to executives by the market research. This is carried out to assist companies in reaching their main goals and making better judgments.

Get Sample Copy Of This Report @ https://www.snsinsider.com/sample-request/3490

Market Segmentation

By Type

Chemotherapy

Monoclonal Antibody

Protease Inhibitors

Others

By Disease Type

Smoldering Multiple Myeloma

Active Multiple Myeloma

By End User

Clinics

Hospitals

Others

Regional Outlook

The geographical categories that make up the Multiple Myeloma Market  each have their own revenue, market share, sales, and growth rates. Among the important geographical areas covered in the market analysis are Europe, Asia-Pacific, South America, North America, and the Middle East and Africa. Latin America is expected to have a small market share in value, while North America is forecast to maintain its global leadership position and have a significant market share in both volume and value.

COVID-19 Impact Analysis

In the first half of 2020, the COVID-19 virus started to spread over the world, infecting millions of people and forcing major nations to implement work stoppage and foot restrictions. Nearly every area of the economy has suffered, with the exception of medical goods and equipment for life support, including the Multiple Myeloma Market .

Competitive Landscape

The competitive analysis section of the global Multiple Myeloma Market  offers details and insights on the participants. Among the details provided are information on competition, a market overview by business status, and revenue projections by region. These businesses use a variety of strategies, such as product launches, partnerships, alliances, technology advancements, and contracts, to boost market income.

Conclusion

The market research is supported by first-hand experience, qualitative and quantitative analysis by industry analysts, and comments from key market players and actors in the value chain. The study investigates parent industry trends, micro and macroeconomic data, governing factors, and market attractiveness on a segment-by-segment basis. The study also illustrates how different market factors might have a qualitative impact on market segmentation based on geography and Multiple Myeloma Market.

About Us

SNS Insider is a market research and insights firm that has won several awards and earned a solid reputation for service and strategy. We are a strategic partner who can assist you in reframing issues and generating answers to the trickiest business difficulties. For greater consumer insight and client experiences, we leverage the power of experience and people.

When you employ our services, you will collaborate with qualified and experienced staff. We believe it is crucial to collaborate with our clients to ensure that each project is customized to meet their demands. Nobody knows your customers or community better than you do. Therefore, our team needs to ask the correct questions that appeal to your audience in order to collect the best information.

Related Reports

Flash Chromatography Market Size

Cystic Fibrosis Market Size

Cancer Biopsy Market Size

Glaucoma Therapeutics Market Size

Genomics Services Market Size

[fairfield-research]

Oncology Drugs Market Growth, Trends, Size, Share, Demand And Top Growing Companies 2031

In a landscape where the battle against cancer rages on, advancements in healthcare systems, public health measures, and novel pharmaceutical therapies have ushered in a new era of hope. According to the National Cancer Institute, the United States saw an estimated 1,806,590 new cancer cases and approximately 606,520 deaths due to the disease in 2020. However, over the past five decades, cancer survival rates have soared from 50% in 1970 to an impressive 70%, thanks to a trifecta of progress.

For more information: https://www.fairfieldmarketresearch.com/report/oncology-drugs-market

Unprecedented Growth Trajectory: The global oncology therapy sales are forecasted to surpass US$ 300 billion by 2026, with oncology contributing 21.7% to total pharmaceutical sales. Fueling this growth are the top 10 pharmaceutical companies, which have declared oncology as their key focus area, driving multibillion-dollar M&A deals and strategic collaborations. Pfizer's acquisition of Array BioPharma for US$11 billion in 2019 and AbbVie's strategic partnership with Genmab for a bispecific antibody development deal worth US$3 billion are testament to this focus.

Diverse Indications Drive Demand: While oncology represents over 20 different indications, a significant portion of revenue stems from just five of them: breast cancer, multiple myeloma, non-small-cell lung carcinoma (NSCLC), prostate cancer, and non-Hodgkin's lymphoma (NHL), which collectively accounted for approximately 65% of the market in 2020. Moreover, with breast, lung, and colorectal cancers expected to collectively account for ~50% of all new cancer diagnoses by 2026, the demand for innovative therapies continues to surge.

Disruptive Trends Reshape Landscape: Innovation in oncology is accelerating, with disruptive technologies such as cell therapy, RNA therapy, viral vectors, and stem cell therapy gaining traction. Recent approvals of CAR-T cell therapies like Kymriah and Yescarta for acute lymphocytic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) respectively signal a new frontier in cancer treatment. Precision medicine is also driving progress, with over 160 oncology biomarkers approved by 2019, paving the way for more targeted and effective therapies.

Impact of COVID-19: Despite remarkable progress, oncology has been among the worst-hit therapeutic areas amid the COVID-19 pandemic. Decreased demand for physician-administered products, disruptions in cancer screenings, and a decline in new clinical trials have posed significant challenges. However, the industry remains resilient, adapting to the evolving landscape and ensuring continued innovation.

Immuno-Oncology Leads the Way: Immuno-oncology sales are expected to soar to ~US$ 95 billion by 2026, with agents and protein kinase inhibitors comprising ~65% of sales. With over 550 active cell- and gene-therapy agents under clinical development, the future of cancer treatment looks promising. Investments in combination studies and the exploration of new mechanisms underscore the industry's commitment to advancing immuno-oncology therapies.Roche and Keytruda: Leading the Charge: In a highly concentrated market where the top 10 companies capture over 75% of the market value, F. Hoffmann-La Roche AG (Roche) and Merck & Co. stand out as leaders. While Roche maintains its global leadership position, Merck's Keytruda is poised to become the world's top-selling oncology

[delvenservices]

Relapsed Refractory Multiple Myeloma Market Research Analysis

Relapsed/Refractory Multiple Myeloma (RRMM) Market, by Drug Type (Proteosome Inhibitor and Immunomodulators), Route of Administration (Oral and Parenteral), Product Type (Tablet, Capsule, Solution, Suspension), End User (Hospitals, Surgical Centres/ Clinics), and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).

Market Overview

The Relapsed/Refractory Multiple Myeloma (RRMM) market size was estimated at USD 2.2 billion in 2023 and is projected to reach USD 3.12 billion in 2030 at a CAGR of 4.5% during the forecast period 2023-2030.

New drugs have significantly improved the prognosis of MM, which is a type of cancer that affects plasma cells in the bone marrow. The development of multiple generations of new drugs has led to a wider range of treatment options for both newly diagnosed and relapsed/refractory MM patients. This increase in therapeutic alternatives has expanded the clinical scenario, meaning that doctors now have more options to choose from when treating MM patients. The availability of more treatment options is particularly important for RRMM patients, who have already undergone one or more rounds of treatment and may have developed resistance to certain drugs. The development of new drugs has also led to improvements in overall survival rates for MM patients, as well as longer periods of remission.

several generations of new drugs have been developed since the first decade of the 21st century, which has significantly improved the prognosis of MM. The availability of new therapeutic options has led to increased complexity in treatment approaches, as there are now more options to consider for both newly diagnosed and relapsed/refractory MM (RRMM) patients. Despite the increased complexity, the availability of new therapeutic options has extended progression-free and overall survival for RRMM patients in meaningful ways. This suggests that the development of new drugs has not only improved patient outcomes but also has economic implications for the pharmaceutical industry.

The COVID-19 pandemic has had a significant impact on businesses across all industries, including the healthcare and pharmaceutical sectors. In response to this, the U.S. Food and Drug Administration (FDA) has released guidelines to help ensure the safety of trial participants and maintain the integrity of clinical trials during the pandemic. These guidelines include general considerations that sponsors and researchers should take when conducting clinical trials during the COVID-19 health emergency. One of the key considerations is to follow good clinical practice (GCP), which is a set of ethical and scientific quality standards for designing, conducting, recording, and reporting clinical trials.

Request Sample Pages of Report: https://www.delvens.com/get-free-sample/relapsed-refractory-multiple-myeloma-rrmm-market-trends-forecast-till-2030

Delvens Industry Expert's Standpoint

RRMM (Relapsed Refractory Multiple Myeloma) is a type of cancer that is difficult to treat due to its complexity and the wide variety of clinical situations found in MM (Multiple Myeloma) patients before they reach the status of relapsed/refractory disease. The availability of new therapeutic options has extended progression-free and overall survival for RRMM patients in meaningful ways. These treatments are not curative, but they have improved patient outcomes and increased the number of therapeutic options available. The development of new therapies has been a key driver of the RRMM market. The emphasis on individualized treatment and the projected market growth further contribute to the expansion of the RRMM market. Individualized treatment approaches are necessary due to the complexity of RRMM. These approaches take the patient's unique clinical situation, including their age, overall health, and previous treatments. The use of individualized treatment approaches has led to the development of new therapies that target specific genetic mutations or other factors that contribute to the development of RRMM. Overall, the availability of new therapeutic options and the emphasis on individualized treatment approaches have improved patient outcomes and increased the number of treatment options available for RRMM patients.

Key Findings

On the basis of drug type, RRMM stands for Relapsed and Refractory Multiple Myeloma, which is a type of cancer that affects plasma cells in the bone marrow. The market trend analysis provided by the RRMM segment helps to understand the current and future market scenario of drugs used to treat this type of cancer. This segmentation is important because it allows pharmaceutical companies and investors to identify the most promising drugs and therapies in the market and make informed decisions about investment and development strategies. By analyzing the market trend of each drug and therapy, the RRMM segment can provide insights into factors such as efficacy, safety, pricing, and competition, which are critical for success in the pharmaceutical industry. The RRMM segment is particularly relevant for companies that are developing new drugs and therapies for the treatment of relapsed and refractory multiple myeloma, as it can help them to identify unmet needs in the market and develop products that address those needs.  

On the basis of product type, RRMM stands for relapsed, refractory, and relapsed/refractory multiple myeloma, which are specific criteria used to define a certain type of multiple myeloma. Relapsed multiple myeloma refers to when the disease returns after a period of remission, while refractory multiple myeloma refers to when the disease does not respond to treatment or stops responding after an initial response. Relapsed/refractory multiple myeloma refers to when the disease both returns after a period of remission and does not respond to treatment or stops responding after an initial response. Identifying patients who meet the criteria for RRMM is important because they may require different treatment options than those with newly diagnosed multiple myeloma.  

On the basis End-User, Patients with MM may experience relapsed/refractory disease, which means that the cancer has returned or is not responding to treatment. Before reaching this stage, MM patients may experience various clinical situations, such as partial response or stable disease, which can be used to segment the RRMM (relapsed/refractory MM) market. Segmentation refers to the process of dividing a market into smaller groups based on specific characteristics, such as disease stage or treatment history. By segmenting the RRMM market based on clinical situations, healthcare professionals can better understand the complexity of treatment approaches for this patient population. This understanding can help inform treatment decisions and improve patient outcomes by tailoring therapies to specific clinical situations.

The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period.

To Grow Your Business Revenue, Make an Inquiry Before Buying at: https://www.delvens.com/Inquire-before-buying/relapsed-refractory-multiple-myeloma-rrmm-market-trends-forecast-till-2030

Regional Analysis

North America to Dominate the Market

North America is estimated to account for the largest market share during the forecast period. There are many manufacturers and suppliers in North America. As a result of the region's rapid economic growth, industrial production has expanded, feeding the desire for the treatment of multiple myeloma.  

New items or technology for treatment emerge. Rising technological developments, governmental approvals and introducing new products for market growth.

Competitive Landscape

Celgene Corporation

Amgen Inc

Janssen Pharmaceuticals

Takeda Pharmaceutical Company Limited

GlaxoSmithKline plc

Sanofi

AbbVie Inc.

Bristol Myers Squibb

Novartis AG

Bristol-Myers Squibb Company

Johnson & Johnson

Teva Pharmaceutical Industries

ONO Pharmaceutical

Merck KGaA

Bausch Health Companies Inc.

Sun Pharmaceutical Industries Ltd

Aurobindo Pharma

Hikma Pharmaceuticals PLC

Recent Developments

In January 2022, Bristol-Myers Squibb, a pharmaceutical company, announced that Japan’s Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma.  

In June 2022, Sap acquired Askdata to strengthen its ability to help organizations take better-informed decisions by leveraging AI-driven natural language searches. Users are empowered to search, interact, and collaborate on live data to maximize business insights.

Direct Order for the Research Report at: https://www.delvens.com/checkout/relapsed-refractory-multiple-myeloma-rrmm-market-trends-forecast-till-2030

Reasons to Acquire

Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.  

Gain authentic and granular data access for the Relapsed/Refractory Multiple Myeloma (RRMM) Market to understand the trends and the factors involved in changing market situations.  

Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.  

In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope

The Relapsed/Refractory Multiple Myeloma (RRMM) Market is segmented into various segments such as Drug Type, Product Type, Route of Administration, End-User, and Region:

Based on Drug Type

Proteosome Inhibitor

Immunomodulators

Anti-CD38 Monoclonal Antibody

Others

Based on the Route of Administration

Oral

Parenteral

Based on the Product Type

Tablet 

Capsule

Solution

Suspension

Based on End-User

Hospitals

Surgical centres

Others

The prominent players in the Relapsed/Refractory Multiple Myeloma (RRMM) market are

Celgene Corporation

Amgen Inc

Janssen Pharmaceuticals

Takeda Pharmaceutical Company Limited

GlaxoSmithKline plc

Sanofi

AbbVie Inc.

Bristol Myers Squibb

Novartis AG

Bristol-Myers Squibb Company

Johnson & Johnson

Teva Pharmaceutical Industries

ONO Pharmaceutical

Merck KGaA

Bausch Health Companies Inc.

Sun Pharmaceutical Industries Ltd

Aurobindo Pharma

Hikma Pharmaceuticals PLC

Read Related Industry Reports:

The Relapsed/Refractory Multiple Myeloma (RRMM) Market report answers a number of crucial questions, including:

Which companies dominate the Relapsed/Refractory Multiple Myeloma (RRMM) Market?

What current trends will influence the market over the next few years?

What are the market's opportunities, obstacles, and driving forces?

What predictions for the future can help with strategic decision-making?

What advantages does market research offer businesses?

Which particular market segments should industry players focus on in order to take advantage of the most recent technical advancements?

What is the anticipated growth rate for the market economy globally?

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

Contact Us:

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

+44-20-8638-5055

SALES@DELVENS.COM

[avajones]

Hematological Cancers Therapeutics Market Revenue Trends, Company Profiles, Revenue Share Analysis, 2022–2032

The global Hematological Cancers Therapeutics Market is expected to experience significant growth in the coming years. The market size was USD 66.77 billion in 2022 and is projected to reach USD 122.75 billion by 2032, with a rapid compound annual growth rate (CAGR) of 7% during the forecast period. The increasing prevalence of hematological cancer, advancements in Research & Development (R&D), and the growing demand for personalized treatment are major factors driving the market's revenue growth.

Hematological cancer, also known as blood cancer, refers to a type of cancer that affects the blood, bone marrow, or lymphatic system. The need for medicines is rising due to the increasing prevalence of hematological malignancies worldwide. According to the American Cancer Society, it is estimated that there will be around 196,060 new cases of hematological cancer in the U.S. in 2022, with approximately 83,040 deaths from these diseases.

Get a sample of the report @ https://www.reportsanddata.com/download-free-sample/1068

Major players in the global hematological cancers therapeutics market include

AbbVie Inc.

Amgen Inc.

AstraZeneca plc

Bristol-Myers Squibb Company

Celgene Corporation

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline plc

Johnson & Johnson

Novartis International AG

Pfizer Inc.

The development of novel treatments resulting from improvements in R&D efforts is driving the demand for hematological cancer medicines. For example, in June 2021, the U.S. Food and Drug Administration (FDA) approved a novel treatment for multiple myeloma, a type of hematological cancer. This treatment utilizes a monoclonal antibody that selectively targets specific immune system cells.

Furthermore, the rising demand for personalized medicine is another factor contributing to market revenue growth. Personalized medicine aims to improve patient outcomes by tailoring their care based on their unique needs, genetic makeup, medical history, and other characteristics. The use of customized treatments for hematological cancer is increasing, leading to improved patient outcomes.

Targeted therapy, which focuses on specific proteins or genes involved in the initiation and spread of cancer, has proven to be less harmful and more effective than conventional chemotherapy.

Moreover, the increasing investment in R&D is expected to drive market revenue growth. Government entities, commercial businesses, and academic institutions are significantly funding R&D efforts to develop novel therapies for hematological cancers. For example, the National Cancer Institute (NCI) allocated over USD 136 million to hematological cancer research in 2021.

To know more about the report @ https://www.reportsanddata.com/report-detail/hematological-cancers-therapeutics-market

However, factors such as the high cost of medicines, adverse effects of hematological cancer therapeutics, and the availability of alternative treatment options could restrain the market's revenue growth. The high cost of hematological cancer therapies, particularly in developing nations, limits their widespread use. Additionally, the adverse effects of these therapies, such as significant fatigue, nausea, and hair loss, can make it challenging for patients to adhere to their treatment plans, thereby impacting market revenue growth.

Overall, while the hematological cancers therapeutics market is expected to witness substantial growth, challenges such as cost, side effects, and alternative treatments need to be addressed to fully realize the market's potential. Continued advancements in R&D and the development of more targeted and personalized therapies are likely to drive the market forward.

Therapy Type Outlook (Revenue, USD Billion; 2019-2032)

Chemotherapy

Targeted Therapy

Immunotherapy

Stem Cell Transplantation

Indication Outlook (Revenue, USD Billion; 2019-2032)

Leukemia

Lymphoma

Multiple Myeloma

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1068

Regional Outlook (Revenue, USD Billion; 2019–2032)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Key Advantages of Hematological Cancers Therapeutics Report:

Identification and analysis of the market size and competition

Qualitative and quantitative analysis of the market data

Data validated by industry experts after extensive primary and secondary research

Extensive regional analysis of the Hematological Cancers Therapeutics industry

Profiling of key players along with their business overview,  business strategies, deals and partnerships, and product portfolio

SWOT and Porter’s Five Forces Analysis for in-depth understanding of the competitive landscape

Feasibility analysis and investment analysis to enable strategic investment decisions

Analysis of opportunities, drivers, restraints, challenges, risks, and limitations

Conclusively, all aspects of the Hematological Cancers Therapeutics market are quantitatively as well qualitatively assessed to study the global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and its future prospects.

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Contact Us:John W Head of Business Development Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com Reports and Data | Web: www.reportsanddata.com

[reallyzealousnight]

Cancer Immunotherapy Market Opportunity Analysis and Industry Forecast 2021-2025

Cancer Immunotherapy Market by Technology (Monoclonal Antibodies, Cytokines and Immunomodulators, and Others), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others), and End User (Hospitals, Cancer Research Centers, and Clinics): Global Opportunity Analysis and Industry Forecast 2021-2025

The cancer immunotherapy market is expected to grow at a CAGR of 13.8% from 2018 to 2024 to reach USD 152.83 billion by 2025. Cancer immunotherapy has emerged as a new source of revenue for pharmaceutical firms. Furthermore, the adverse effects of conventional chemotherapies, such as cancer recurrence and organ failure, as well as the growing demand for technologically advanced healthcare solutions, are driving up demand for immunotherapies. Furthermore, the introduction of newer drug classes, such as multiple myeloma target receptors and checkpoint inhibitors, is expected to pave the way for advanced therapeutics in the market.

Download Sample PDF  :-  https://www.meticulousresearch.com/request-sample-report/cp_id=4690

The cancer immunotherapy market is divided into five applications: lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, and others. The lung cancer market held the largest share in 2020 and is expected to lead the market during the analysis period due to the high incidence of lung cancer worldwide and an increase in the awareness programme regarding the need for early lung cancer therapeutics.

Scope Of Report :-

By Technology Type

Monoclonal     Antibodies

Cytokines     & Immunomodulators

Others

By Application

Lung Cancer

Breast Cancer

Colorectal     Cancer

Melanoma

Prostate     Cancer

Head &     Neck Cancer

Others

By End user

Hospitals

Cancer     Research Centers

Clinics

By Region

 U.S.

 Canada

 Mexico

 Germany

 France

 UK

 Italy

 Spain

 Rest of      Europe

 Japan

 China

 India

 Rest of      Asia-Pacific

 Latin America

 Middle East

 Africa

Key Benefits For Stakeholders

·         The study provides an in-depth analysis of the global cancer immunotherapy market size, as well as current trends and future projections, to help stakeholders identify potential investment opportunities.

·         It provides market analysis from 2021 to 2030, which is expected to enable stakeholders to capitalise on the current opportunities in the cancer immunotherapy market.

·         A comprehensive regional analysis aids in understanding the regional market, facilitating strategic business planning and determining current opportunities.

·         The profiles and growth strategies of the key players are thoroughly examined in order to comprehend the competitive landscape of the global cancer immunotherapy market.

For More Insights   :-   https://www.meticulousresearch.com/product/cancer-immunotherapy-market-4690

About Us :

We are the trusted research partners for leading businesses around the world, providing market intelligence focused towards building revenue transformation strategies. Our research is used by Fortune 500 organizations to attain success by scouting next generation revenue opportunities well ahead of their competition.

Through our mixed bag of research offerings – syndicated research, custom research, and analyst engagement — we enable smart decision making to enhance business performance for global organizations. Our focus is also on finding answers to the challenging questions that global business leaders face on a daily basis. Each year, we deliver more than 300 syndicate studies and 60+ consulting projects across eight industry verticals in 20+ geographic markets.

Contact: Mr. Khushal Bombe Meticulous Market Research Inc. 1267 Willis St, Ste 200 Redding,  California, 96001, U.S. USA: +1-646-781-8004 Europe : +44-203-868-8738 APAC: +91 744-7780008 Email- sales@meticulousresearch.com 

[jesse-pinkman123]

Hematopoietic Stem Cell Transplantation (HSCT) Market To Surpass Us$ 4,391.0 Million By 2027

The process of hematopoietic stem cell transplantation involves the intravenous infusion of hematopoietic stem cells. The process aims to reestablish blood cell production in patients whose bone marrow or immune system is damaged or defective. Bone marrow is the soft, spongy area in the center of some of the larger bones of the body.

The global hematopoietic stem cell transplantation market is estimated to be valued at US$ 2,092.6 million in 2020 and is expected to exhibit a CAGR of 11.2% during the forecast period (2020-2027).

Global Hematopoietic Stem Cell Transplantation (HSCT) Market: Drivers

Increasing number of hematopoietic stem cell transplants is expected to propel growth of the global hematopoietic stem cell transplantation (HSCT) market over the forecast period. For instance,  the number of peripheral blood hematopoietic cell transplants (HCTs) performed in the U.S. increased from 21,487 in 2015 to 22,863 in 2017, according to the Center for International Blood and Marrow Transplant Research Transplant Activity Report.

Market Trends

Asia Pacific is expected to witness significant growth in the global hematopoietic stem cell transplantation (HSCT) market, owing to increasing number of HSCT transplants in the region. For instance, the number of transplants in Japan increased from 5468 in 2012 to 5904 in 2017, according to the Japanese Data Center for Hematopoietic Cell Transplantation.

Request Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/1250

North America accounted is also expected to witness significant growth in the global hematopoietic stem cell transplantation (HSCT) market, owing to high prevalence of leukemia. For instance, according to National Cancer Institute, the U.S. is expected to record 6,150 new cases of acute lymphocytic leukemia in 2020. ALL is highly prevalent in children between the ages of 2 and 4 years. According to Leukemia and Lymphoma Society’s 2018-2019 facts, the incidence of acute lymphoblastic leukemia was 7.8 (per 100,000) in children aged 1-4 years during 2011-2015

Global Hematopoietic Stem Cell Transplantation (HSCT) Market: Competitive Landscape  

Major players operating in the global hematopoietic stem cell transplantation (HSCT) market include, Bluebird Bio, CellGenix GmbH, Escape Therapeutics, Inc., Kiadis Pharma, Lonza Group, Marker Therapeutics Inc., Pluristem Therapeutics Inc., Regen Biopharma Inc., Stempeutics Research Pvt Ltd., Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, and Talaris Therapeutics, Inc.  

Global Hematopoietic Stem Cell Transplantation (HSCT) Market: Key Developments    

Major players operating in the global hematopoietic stem cell transplantation (HSCT) market are focused on R&D to expand their product portfolio. For instance, in July 2021, Vor Biopharma, a founded entity of PureTech Health plc, a clinical-stage biotherapeutics company based in the U.S., collaborated with Janssen Biotech, Inc. to develop engineered hematopoietic stem cell transplants combined with a bi-specific antibody therapy for acute myeloid leukemia.

Global Hematopoietic Stem Cell Transplantation (HSCT) Market: Segmentation

On the basis of transplant type, the global hematopoietic stem cell transplantation (HSCT) market is segmented into:

·         Allogeneic

·         Autologous

On the basis of indication, the global hematopoietic stem cell transplantation (HSCT) market is segmented into:

·         Acute Myeloid Leukemia (AML)

·         Acute Lymphoblastic Leukemia (ALL)

·         Hodgkin lymphoma (HL)

·         Non-Hodgkin Lymphoma (NHL)

·         Multiple Myeloma (MM)

·         Other Non-malignant Disorders

On the basis of application, the global hematopoietic stem cell transplantation (HSCT) market is segmented into:

·         Bone Marrow Transplant (BMT)

·         Peripheral Blood Stem Cells Transplant (PBSCT)

·         Cord Blood Transplant (CBT)

On the basis of region, the global hematopoietic stem cell transplantation (HSCT) market is segmented into:

·         North America

·         Latin America

·         Europe

·         Asia Pacific

·         Middle East

·         Africa

Buy Now this Research Report: https://www.coherentmarketinsights.com/insight/buy-now/1250

About US:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

 Contact Us:

Coherent Market Insights

1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Email: sales@coherentmarketinsights.com

United States of America: +1-206-701-6702

United Kingdom: +44-020-8133-4027

Japan: +050-5539-1737

India: +91-848-285-0837

[healthcare-market]

Impact of COVID-19 on CAR T-cell Therapy Market

CAR T-cell Therapy Market: Introduction

According to the report, the global CAR T-cell therapy market was valued at US$ 1.1 Bn in 2020 and is projected to expand at a CAGR of 30.6% from 2021 to 2031. CAR T-cell therapy is a recently approved treatment option for various types of cancer. CAR T cell therapy is provided by removing or harvesting T cells from a patient with cancer, transfecting the cells with CAR genes that are directed against the patient’s tumor type, expanding the modified T cell population, and reinfusing the cells back into the patient. Currently, Kymriah, Yescarta, Tecartus, Breyanzi, and ABECMA are the CAR T-cell therapy approved products for acute lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, multiple myeloma, and others.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=83242

The global CAR T-cell therapy market is driven by increase in incidence of cancer and strong product pipeline. North America dominated the global CAR T-cell therapy market in 2020 and the trend is anticipated to continue during the forecast period. Highly structured healthcare industry, early adoption of new products, high prevalence rate of cancer, and presence of major players are expected to propel the CAR T-cell therapy market in North America. Asia Pacific is likely to be a highly lucrative market for CAR T-cell therapy during the forecast period. The market in the region is projected to expand at a high CAGR from 2021 to 2031.

Request for Analysis of COVID19 Impact on CAR T-cell Therapy Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=83242

Increase in Incidence of Cancer and Strong Product Pipeline to Drive Global Market

Increase in incidence of cancer and strong product pipeline are anticipated to boost the growth of the global CAR T-cell therapy market. According to the WHO, one in five people develop cancer during their lifetime, and one in eight men and one in 11 women die from the disease. These new estimates suggest that more than 50 million people are living within five years of a past cancer diagnosis. According to the WHO, in 2020, around 544,352 new cases of non-Hodgkin lymphoma were recorded globally.

Strong product pipeline is a major factor driving the demand for CAR T-cell therapy products. For instance, Autolus Therapeutics plc has one innovative product, AUTO1, in phase I trial for treatment of adult acute lymphoblastic leukemia. AUTO1 contains obecabtagene autoleucel, which is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=83242

Axicabtagene Ciloleucel to Dominate CAR T-cell Therapy Market

In terms of product type, the global CAR T-cell therapy market has been classified into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, idecabtagene vicleucel, and others. The axicabtagene ciloleucel segment dominated the global CAR T-cell therapy market in 2020 and the trend is expected to continue during the forecast period. Yescarta is a product, which contains axicabtagene ciloleucel. Increase in demand for Yescarta in the treatment of diffuse large B-cell lymphoma and follicular lymphoma is likely to boost the growth of the segment during the forecast period. In October 2017, Kite Pharma, Inc. received the U.S. FDA approval for Yescarta for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

Tisagenlecleucel was the second largest segment in terms of market share in 2020. Increase in demand for Kymriah for treatment of acute lymphoblastic lymphoma and product approval in different countries are likely to drive the segment.

Enquiry before Buying CAR T-cell Therapy Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=83242

Diffuse Large B-cell Lymphoma to be Highly Lucrative

Based on indication, the global CAR T-cell therapy market has been categorized into acute lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, multiple myeloma, and others. The diffuse large B-cell lymphoma segment dominated the CAR T-cell therapy market due to increase in incidence of diffuse large B-cell lymphoma. Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Increase in number of cases of non-Hodgkin lymphoma is likely to propel the segment during the forecast period. According to WHO, globally, around 544,352 new non-Hodgkin lymphoma cases were recorded in 2020.

Hospitals to Emerge as Significant End-user

In terms of end-user, the global CAR T-cell therapy market has been divided into hospitals and cancer treatment centers. The hospitals segment led the global CAR T-cell therapy market in terms of revenue in 2020 and the trend is projected to continue during the forecast period. The hospitalization for cancer treatment is anticipated to boost the growth of the hospitals segment. Moreover, increase in use of CAR T-Cell therapy in the treatment of cancers contributes to the segment's large market share. The segment is driven by surge in number of cancer patients who visit hospital for treatment of cancer.

Buy now CAR T-cell Therapy Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=83242&ltype=S

North America to Dominate CAR T-cell Therapy Market

In terms of region, the global CAR T-cell therapy market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global CAR T-cell therapy market in 2020, followed by Europe. North America’s large market share can be ascribed to technologically advanced research and treatment platforms, increase in number of cancer patients, new product launches, and presence of major players. The CAR T-cell therapy market in Asia Pacific is anticipated to expand at a high CAGR from 2021 to 2031. This can be ascribed to the presence of developing countries with commercial hubs, expansion of business organizations, rise in awareness about CAR T-cell therapy, improvement in healthcare infrastructure, and increase in investments by companies.

Competition Landscape

The global CAR T-cell therapy market is consolidated due to limited approved products. Key players operating in the global market include Pfizer, Inc., Novartis AG, Bristol-Myers Squibb, Amgen, Inc., Sorrento Therapeutics, Inc., Johnson & Johnson Services, Inc., Gilead Sciences, Inc., Merck & Co., Inc., and bluebird bio, Inc.

More Trending Reports by Transparency Market Research:

D-dimer Testing Market D-dimer tests are used for diagnosing conditions related broadly to deep vein thrombosis (DVT), pulmonary embolism, and disseminated intravascular coagulation (DIC). Among all the applications, the demand for the test for diagnosing DVT is prominent.

Pyrogen Testing Market North America dominated the global pyrogen testing market in 2018and the trend is anticipated to continue during the forecast period. New drug approvals by the Food and Drug Administration (FDA) and increase in demand for pyrogen testing for medical devices are expected to drive the pyrogen testing market in North America.

Conserving Devices Market While nasal cannulae for supplementary supply of oxygen is reliable and effective, it is very wasteful. To address this, oxygen conserving methodologies have emerged to improve the efficiency of oxygen delivery for patients requiring oxygen therapy. This is because oxygen conserving devices enable a high degree of portability, improve the efficiency of oxygen delivery, and lighten the load for these patients.

About Us Section:

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!

Contact Us

Mr. Rohit Bhisey Transparency Market Research, 90 State Street, Suite 700, Albany, NY 12207 Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

[bitchyphilosopherprince]

Global B Cell Maturation Antigen (BCMA) Market Size, Study, by Product, Application and Forecasts 2021-2026

Bharat Book Bureau Provides the Trending Market Research Report on “Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026”under  Life Sciences Market Research Reports Category. The report offers a collection of superior market research, market analysis, competitive intelligence and Market reports.

Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights: • Research Methodology • Global & Regional Market Analysis • Global BCMA Targeted Drugs Market Opportunity Assessment: > USD 4 Billion • Market and Drug Sales Insight 2020 Till 2026 • Approved Drug In Market: 2 Drugs • Approved BCMA Targeted Drugs Patent, Price and Sales insight 2020 Till 2026 • Future Market Assessment By Indication Till 2026 • Ongoing Clinical Trials Assessment by Status, Phase & Region • Key Market Dynamics • Competitor Landscape

Over a period of time, the cancer research has deviated for conventional approach and is directed towards the development of novel drugs that selectively targets the oncogenes, thereby reducing the adverse side effects. Genomic analysis have shown that B-cell maturation antigen or CD269 is restrictively expressed in both normal as well as malignant cells at high levels, thus making it an ideal target antigen for development of novel multiple myeloma therapies. BCMA is a member of tumor necrosis factor family and has critical role in the regulating B-cell proliferation and survival. The interaction of BCMA with its ligand has also shown to promote the progression of cancer. Further, studies have also demonstrated that BCMA is central to the survival of multiple myeloma cells. Therefore, researchers have adopted several approaches to target this antigen as an alternative for the management of multiple myeloma.

Currently, multiple innovative BCMA-targeted treatment modalities, including antibody-drug conjugate (ADC), CAR-T cells, and bispecific T cell engager (BiTE), are under active clinical development. However, two BCMA targeted drug modalities have also entered the market. Belantamab mafodotin (Blenrep) developed by GlaxoSmithkline was the first BCMA targeted drug approved for patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. It is an antibody drug conjugate which consists of humanized anti-BCMA IgG1 monoclonal antibody conjugated to monomethyl auristatin F (MMAF, mafodotin) via a non-cleavable maleimidocaproyl (MC) linker.

In April 2021, Abecma developed by Bristol Meyer Squibb has also gain entry into market for the management of multiple myeloma. Abecma is BCMA directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy which is approved for the same indication. The entry of Abecma in the market is expected to have a negative impact on the growth of Blenrep sales which is mainly due to its novel mechanism of action, better survival rates, and ability to overcome the limitations of Blenrep. As per our analysis, Abecma will dominate the market during the forecast period. Apart from multiple myeloma, researchers are also evaluating the role of these drugs in other therapeutic conditions including AL Amyloidosis, and various subtypes of lymphoma which will further drive the growth of market. In addition, several ongoing clinical trials are also evaluating the use of Abecma in combination with other modalities including pembrolizumab, dexamethasone, and other chemotherapeutic agents which aim to enhance the efficacy of the treatment, which will boost this segment during forecast period.

The active research and development in this sector will drive the growth of the market. At present, several BCMA targeting drugs including ciltacabtagene autoleucel, Allo715, CTX-120, MCARH171, and others are present in clinical pipeline which are expected to gain approval during the forecast period. For instance, US FDA has recently granted priority review for ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy developed by Janssen. The rapid approval of these drugs during the forecast period will also drive the growth of market.

The global BCMA targeted drugs market is expected to witness high growth rates during the forecast period attributing mainly to the increase in prevalence of cancers and rates at which conventional therapies are failing. Moreover, key players in the market are strategically partnering and collaborating to expand the product portfolio and geographical presence of the company. Amid region, North America dominated the global market which is mainly credited to the growing number of research and development activities, presence of large pharmaceutical sector and high adoption rates of already approved therapies. Other regions such as Europe, Asia-Pacific are also expected to grow at high rates due to increase in prevalence of disorders and rising awareness among the population.

Browse our full report with Table of Content : https://www.bharatbook.com/report/995041/global-b-cell-maturation-antigen-bcma-targeted-therapy-market-clinical-trials-insight

About Bharat Book Bureau: Bharat Book is Your One-Stop-Shop with an exhaustive coverage of 4,80,000 reports and insights that includes latest Market Study, Market Trends & Analysis, Forecasts Customized Intelligence, Newsletters and Online Databases. Overall a comprehensive coverage of major industries with a further segmentation of 100+ subsectors.

Contact us at: Bharat Book Bureau Tel: +91 22 27810772 / 27810773 Email: poonam@bharatbook.com Website: www.bharatbook.com

[newsupdate-1]

CAR-T Cell Therapy Market Share, Size, Growth and Regional Outlook

The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Polaris Market Research. The report “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2020 – 2026” provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market.

This market report focuses on CAR-T which is one of the most innovative therapy available in the market which uses the patients’ immune cells to fight cancer. The WBCs (white blood cells) are extracted – reengineered – injected again into the patient body to fight the malignant cells. This novel therapy has joined the bandwagon of the cancer cure treatments and it is expected to be one the sought-after therapies in the market. Majority of the companies have already started investing in them to gain a better market share in this industry.  

Get Sample copy of this report: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-sample

It can be seen that the business scenario of the market is dynamic and major companies are competing with each other to increase their market share in the major geographies of U.S. and Europe. For example, Novartis and Gilead came-up with 33 and 28 authorized centers respectively in U.S. Some of the major companies in this space such as Celgene are expected to file for FDA approvals for two more CAR-Ts lisocabtagene maraleucel in lymphoma and bb2121 (idecabtagene vicleucel) in myeloma.

Along with opening new centers and acquiring necessary government approvals, the companies are also focusing on partnerships, acquisitions and mergers. For instance, Celgene acquired Juno Therapeutics in November 2018 for approximately $9 billion in 2018 and further Bristol-Myers Squibb completed its acquisition of Celgene in November 2019.

Some major key players in global CAR-T Cell Therapy Market includes Bluebird Bio (US), Celgene Corporation (US), Gilead Sciences, Inc. (US), Cellectis (France), Servier Laboratories (France), Pfizer Inc. (US), Mereck KGaA (Germany), Amgen Inc. (US), Intellia Therapeutics (US), Novartis International AG (Swiss), Caribou Biosciences, Inc. (US), Celyad (Belgium), Bellicum Pharmaceuticals, Inc. (US), Noile-Immune Biotech (Japan), Nanjing Legend Biotechnology Co., Ltd. (China), Johnson & Johnson (US), Sangamo Therapeutics, Inc. (US) among others.

Request For Discount: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-discount-pricing

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world

Contact us

Polaris Market Research

Phone: 1-646-568-9980

Email: sales@polarismarketresearch.com

Web: www.polarismarketresearch.com

[udaycmi]

CAR-T Cell Therapy Market Share, Demand, Business Opportunities & Forecasts

The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Polaris Market Research. The report “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2020 – 2026” provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market.

This market report focuses on CAR-T which is one of the most innovative therapy available in the market which uses the patients’ immune cells to fight cancer. The WBCs (white blood cells) are extracted – reengineered – injected again into the patient body to fight the malignant cells. This novel therapy has joined the bandwagon of the cancer cure treatments and it is expected to be one the sought-after therapies in the market. Majority of the companies have already started investing in them to gain a better market share in this industry.  

Get Sample copy of this report: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-sample

It can be seen that the business scenario of the market is dynamic and major companies are competing with each other to increase their market share in the major geographies of U.S. and Europe. For example, Novartis and Gilead came-up with 33 and 28 authorized centers respectively in U.S. Some of the major companies in this space such as Celgene are expected to file for FDA approvals for two more CAR-Ts lisocabtagene maraleucel in lymphoma and bb2121 (idecabtagene vicleucel) in myeloma.

Along with opening new centers and acquiring necessary government approvals, the companies are also focusing on partnerships, acquisitions and mergers. For instance, Celgene acquired Juno Therapeutics in November 2018 for approximately $9 billion in 2018 and further Bristol-Myers Squibb completed its acquisition of Celgene in November 2019.

Some major key players in global CAR-T Cell Therapy Market includes Bluebird Bio (US), Celgene Corporation (US), Gilead Sciences, Inc. (US), Cellectis (France), Servier Laboratories (France), Pfizer Inc. (US), Mereck KGaA (Germany), Amgen Inc. (US), Intellia Therapeutics (US), Novartis International AG (Swiss), Caribou Biosciences, Inc. (US), Celyad (Belgium), Bellicum Pharmaceuticals, Inc. (US), Noile-Immune Biotech (Japan), Nanjing Legend Biotechnology Co., Ltd. (China), Johnson & Johnson (US), Sangamo Therapeutics, Inc. (US) among others.

Request For Discount: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-discount-pricing

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world

Contact us

Polaris Market Research

Phone: 1-646-568-9980

Email: sales@polarismarketresearch.com

Web: www.polarismarketresearch.com